Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

J&J forecasts $2.5 billion in 2021 COVID-19 vaccine sales, sets lower production target

Stock MarketsJul 21, 2021 12:26PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. FILE PHOTO: A Johnson & Johnson building is shown in Irvine, California, U.S., January 24, 2017. REUTERS/Mike Blake

By Manas Mishra and Carl O'Donnell

(Reuters) -Johnson & Johnson on Wednesday forecast $2.5 billion in 2021 sales for its COVID-19 shot and set a lower production target for the vaccine as lengthy manufacturing problems took a toll.

The company now expects to produce 500 million to 600 million doses of its one-shot vaccine this year, Chief Financial Officer Joseph Wolk told CNBC on Wednesday, down from its original goal to produce a billion shots this year.

J&J (NYSE:JNJ) offered no timeline on Wednesday for when it would resume production at a problematic Baltimore plant, which had been expected to produce vaccines for Europe and the United States.

The company expects to record more than half of the projected $2.5 billion in sales in the fourth quarter, Wolk said on a conference call to discuss financial results. It reported $164 million in COVID-19 vaccine sales for the second quarter, bringing total sales to $264 million so far.

J&J estimated its vaccine price at $5 per dose in the first half of the year and said it would likely be as much as $8 by year end. The healthcare conglomerate, which promised it would not make a profit on the vaccine during the pandemic, said the fluctuating price reflected the net costs of the vaccine and production volumes.

The $8 price is a bit lower than previous indications. South Africa has said it is paying $10 per dose for both the J&J and the two-shot Pfizer/BioNTech vaccines. AstraZeneca (NASDAQ:AZN) Plc is charging $3 per shot for its two-dose vaccine.

While the J&J shot was authorized in the United States just a few months after those from Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) were cleared, its vaccine sales outlook pales in comparison and reflects the widening gap in the global vaccine race. Pfizer and Moderna have forecast $26 billion and $19.2 billion in annual sales of their vaccines, respectively.

Analysts have said that lower demand for J&J's vaccine should not affect the enormous company's overall financial performance. J&J reported second-quarter earnings per share of $2.35 on sales of $23.3 billion.

Revenue for all the vaccines could jump if health officials determine a round of booster shots is needed should evidence show COVID-19 immunity is waning.

"It is simply too early to provide specific information on a 2022 outlook for our COVID-19 vaccine given the uncertainty on the need for boosters and new variants," Wolk said. J&J had previously said it expected to be able to make as many as 3 billion vaccine doses in 2022.

The J&J vaccine appears to be durable for at least eight months and effective against prevalent coronavirus variants, Wolk said, citing recently published data from laboratory studies.

Because of its one-dose convenience and less onerous storage and shipping requirements, J&J's shot was once touted as an important tool for vaccinations in hard-to-reach areas. But after safety concerns and manufacturing stumbles, it has the lowest uptake in Europe among all the vaccines approved for use, and has also struggled to gain traction in United States.

Its vaccine has been linked to a very rare, potentially life threatening blood clotting condition, similar to AstraZeneca's. U.S. regulators last week also added a warning related to a rare autoimmune disorder.

The U.S. Food and Drug Administration in April said its inspection found a long list of sanitary problems and bad manufacturing practices in the Baltimore factory run by J&J's subcontractor Emergent BioSolutions Inc, shutting down production.

The FDA has so far approved five batches from the Emergent facility since production there was paused, and J&J is working to clear additional doses for use, Wolk said.

J&J did not comment on other issues facing the company, including liability lawsuits related to its talc and pelvic mesh products, or the recall of five of its sunscreen products after it detected a cancer-causing chemical in some samples.

Reuters reported on Sunday, citing sources, that the company is exploring a plan to offload liabilities from widespread Baby Powder litigation into a newly created business that would then seek bankruptcy protection.

J&J shares were up 0.2% at $168.80.

J&J forecasts $2.5 billion in 2021 COVID-19 vaccine sales, sets lower production target

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email